TG Therapeutics Inc vs Tripadvisor Inc Common Stock — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Tripadvisor Inc Common Stock trades at $13.82 (market cap $1.68B). The key difference: TG Therapeutics Inc is far larger — about 4.9× Tripadvisor Inc Common Stock's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| TGTX | TRIP | |
|---|---|---|
Market Cap | $8.26B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $19.14 |
52-Week Low | $26.39 | $9.24 |
Enterprise Value | $8.50B | $1.80B |
Trailing returns across standard periods
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →